Department of Medicine/Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.
J Hypertens. 2012 Jun;30(6):1092-100. doi: 10.1097/HJH.0b013e3283536319.
Hypertensive disorders represent major causes of pregnancy-related maternal mortality worldwide. The current definition and treatment recommendations for elevated blood pressure (BP) during pregnancy in the United States have remained unchanged for many years, unlike the recommendations for hypertension treatment in the general population. Clinical studies have provided convincing evidence that women with hypertensive pregnancy disorders are at both immediate and long-term risk for cardiovascular complications; these findings suggest that consideration be given to lowering the presently recommended BP thresholds, both for the initiation of therapy and for therapeutic targets, and to simplifying the approach to the management of elevated BP in pregnancy. This review focuses on the current treatment strategies for hypertensive pregnancy disorders, new developments in the field of hypertension, in general, and in pregnant patients, in particular, and their potential impact on contemporary BP goals and the use of specific antihypertensive medications in pregnancy.
高血压疾病是全球导致妊娠相关产妇死亡的主要原因之一。与普通人群的高血压治疗建议不同,美国多年来一直未改变对妊娠期间血压升高的现有定义和治疗建议。临床研究为患有妊娠高血压疾病的女性在近期和长期都存在心血管并发症风险提供了令人信服的证据;这些发现表明,应考虑降低目前推荐的血压阈值,无论是为了开始治疗还是为了治疗目标,并简化妊娠期间血压升高的管理方法。本综述重点关注妊娠高血压疾病的当前治疗策略、一般高血压领域的新进展,特别是在妊娠患者中的新进展,以及它们对当代血压目标和妊娠期间特定降压药物使用的潜在影响。